Well Referenced

Tag: adjuvant therapy

Assessment of Breast Cancer Mortality Trends Associated With Mammographic Screening and Adjuvant Therapy From 1986 to 2013 in the State of Victoria, Australia

This 2020 population-based cohort study evaluated breast cancer mortality trends in Victoria, Australia, over a 27-year period, analyzing the relative contributions of mammographic screening and adjuvant therapy. Using data from the Victorian Cancer Registry and BreastScreen Victoria, the researchers applied age-period-cohort modeling to isolate the effects of each intervention. Results

Read More »
June 26, 2025 No Comments

Efficacy and Safety of Silymarin-Containing Antioxidant Serum as an Adjuvant Treatment of Mild-to-Moderate Acne Vulgaris: A Prospective, Open-Label Pilot Study

This 2023 prospective, open-label pilot study assessed the efficacy and safety of a 0.5% silymarin-loaded antioxidant serum (SAS) as an adjunct treatment in 22 Korean patients with mild-to-moderate acne vulgaris. Over four weeks, patients applied the serum twice daily in addition to their regular acne treatments. The study reported reductions

Read More »
June 26, 2025 No Comments

Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy

This 2024 review explores the potential of low-dose naltrexone (LDN) as an adjunct in cancer treatment. LDN functions by transiently blocking the opioid growth factor receptor (OGFr), leading to a compensatory increase in opioid growth factor (OGF) levels, which inhibits cancer cell proliferation. Additionally, LDN modulates the immune system by

Read More »
June 26, 2025 No Comments

Long-Term Results with Adjuvant Ozone Therapy in the Management of Chronic Pelvic Pain Secondary to Cancer Treatment

This 2021 study evaluated the long-term efficacy of adjuvant ozone therapy (O₃T) in managing chronic pelvic pain in cancer survivors. Six patients with refractory pelvic pain, unresponsive to standard treatments, received O₃T via rectal insufflation. Pain levels, assessed using the Visual Analog Scale (VAS), showed significant reductions: continuous pelvic pain

Read More »
June 26, 2025 No Comments

No difference in disease-free survival after oral cancer resection with close tumor margins in patients with and without postoperative radiotherapy

This 2018 retrospective cohort study analyzed outcomes in 418 patients with oral or oropharyngeal squamous cell carcinoma based on margin status post-resection: clear (>5 mm), close (1–5 mm), and positive (≤1 mm). The 5-year disease-free survival (DFS) for patients with clear and close margins was not significantly different (79.3% vs.

Read More »
June 26, 2025 No Comments

Systematic Evaluation of the Clinical Effects of Supportive Mistletoe Treatment Within Chemo- And/or Radiotherapy Protocols and Long-Term Mistletoe Application in Nonmetastatic Colorectal Carcinoma: Multicenter, Controlled, Observational Cohort Study

​A multicenter, controlled, observational cohort study evaluated the effects of supportive mistletoe extract (Iscador) treatment in patients with nonmetastatic colorectal carcinoma undergoing adjuvant therapy. The study involved 804 patients (429 receiving Iscador and 375 controls) across 26 centers, with a median follow-up of 58 months for the Iscador group and

Read More »
June 26, 2025 No Comments

The Effect of an Adjuvant Mistletoe Treatment Programme in Resected Head and Neck Cancer Patients: A Randomised Controlled Clinical Trial

​A randomized controlled trial involving 477 patients with resected head and neck squamous cell carcinoma assessed the efficacy of an adjuvant mistletoe extract treatment. The study found no significant improvement in disease-free survival, with a hazard ratio of 0.959 (95% CI 0.725–1.268), and no differences in immune response or quality

Read More »
June 26, 2025 No Comments